Nymox Pharmaceutical Reports Significant Long-Term Improvement in BPH Symptoms After NX-1207 Treatment in New Multi-Center U.S. Study

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced significant long-term improvement in symptoms of benign prostatic hyperplasia (BPH) in men treated with the Company’s investigational drug NX-1207 in a newly completed clinical study.